
Taking a Closer Look at Lantus, the Case Behind the FTC’s Crackdown on Improper Orange Book Listings
On November 7, the FTC disputed more than 100 patents on asthma inhalers, EpiPens and other drug products that the agency claimed were improperly listed in the Orange Book, a publication of...
Nov 15, 2023
Read Now >